Header Logo

Connection

Michael Liptay to Carcinoma, Non-Small-Cell Lung

Back to Details
This is a "connection" page, showing publications Michael Liptay has written about Carcinoma, Non-Small-Cell Lung.
Michael Liptay
Connection Strength
5.967
Carcinoma, Non-Small-Cell Lung
  1. Smaller incisions for smaller cancers. Oncology (Williston Park). 2015 Mar; 29(3):166; 168.
    View in: PubMed
    Score: 0.394
  2. Status of sentinel lymph node mapping in non-small cell lung cancer. Cancer J. 2015 Jan-Feb; 21(1):17-20.
    View in: PubMed
    Score: 0.390
  3. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.284
  4. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Ann Thorac Surg. 2009 Sep; 88(3):937-43; discussion 944.
    View in: PubMed
    Score: 0.269
  5. Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg. 2010 Mar; 139(3):606-11.
    View in: PubMed
    Score: 0.269
  6. Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
    View in: PubMed
    Score: 0.260
  7. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009 Feb; 4(2):198-202.
    View in: PubMed
    Score: 0.259
  8. Sentinel node mapping in lung cancer. Ann Surg Oncol. 2004 Mar; 11(3 Suppl):271S-4S.
    View in: PubMed
    Score: 0.184
  9. Current concepts in the staging of non-small cell lung cancer. Surg Oncol. 2002 Dec; 11(4):181-90.
    View in: PubMed
    Score: 0.169
  10. Commentary on sentinel lymph node identification with technetium-99m tin colloid in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002 Sep; 124(3):428-30.
    View in: PubMed
    Score: 0.166
  11. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002 Apr 15; 20(8):1984-8.
    View in: PubMed
    Score: 0.162
  12. Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. J Thorac Cardiovasc Surg. 2021 12; 162(6):1605-1618.e6.
    View in: PubMed
    Score: 0.154
  13. Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry. Lung. 2021 06; 199(3):311-318.
    View in: PubMed
    Score: 0.151
  14. Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. Ann Thorac Surg. 2000 Aug; 70(2):384-9; discussion 389-90.
    View in: PubMed
    Score: 0.144
  15. Complications from induction regimens for thoracic malignancies. Perioperative considerations. Chest Surg Clin N Am. 1999 Feb; 9(1):79-95.
    View in: PubMed
    Score: 0.129
  16. Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
    View in: PubMed
    Score: 0.122
  17. Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
    View in: PubMed
    Score: 0.121
  18. Reply. Ann Thorac Surg. 2018 07; 106(1):316-317.
    View in: PubMed
    Score: 0.120
  19. Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
    View in: PubMed
    Score: 0.118
  20. Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. Lung. 2016 08; 194(4):619-24.
    View in: PubMed
    Score: 0.107
  21. Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
    View in: PubMed
    Score: 0.107
  22. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.103
  23. Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
    View in: PubMed
    Score: 0.101
  24. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):307-16.
    View in: PubMed
    Score: 0.099
  25. Comparative effectiveness of neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery for patients with stage IIIA non-small cell lung cancer. Lung Cancer. 2015 Jun; 88(3):267-74.
    View in: PubMed
    Score: 0.099
  26. Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
    View in: PubMed
    Score: 0.096
  27. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Cancer. 2014 Jul 01; 120(13):2060-8.
    View in: PubMed
    Score: 0.093
  28. Prevalence and predictors of neoadjuvant therapy for stage IIIA non-small cell lung cancer in the National Cancer Database: importance of socioeconomic status and treating institution. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):303-12.
    View in: PubMed
    Score: 0.092
  29. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.085
  30. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Diagn Mol Pathol. 2012 Dec; 21(4):207-13.
    View in: PubMed
    Score: 0.084
  31. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
    View in: PubMed
    Score: 0.083
  32. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
    View in: PubMed
    Score: 0.078
  33. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.076
  34. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011 Jul; 92(1):233-41; discussion 241-3.
    View in: PubMed
    Score: 0.076
  35. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
    View in: PubMed
    Score: 0.073
  36. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.073
  37. A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
    View in: PubMed
    Score: 0.072
  38. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
    View in: PubMed
    Score: 0.071
  39. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.070
  40. The incidence of perioperative anastomotic complications after sleeve lobectomy is not increased after neoadjuvant chemoradiotherapy. Ann Thorac Surg. 2009 Sep; 88(3):945-50; discussion 950-1.
    View in: PubMed
    Score: 0.067
  41. Endobronchial colorectal metastasis versus primary lung cancer: a tale of two sleeve right upper lobectomies. Interact Cardiovasc Thorac Surg. 2009 Aug; 9(2):379-81.
    View in: PubMed
    Score: 0.066
  42. Contemporary review on the inequities in the management of lung cancer among the African-American population. J Natl Med Assoc. 2008 Jun; 100(6):683-8.
    View in: PubMed
    Score: 0.062
  43. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer. 2004 Aug; 45(2):243-53.
    View in: PubMed
    Score: 0.047
  44. Critical factors for patient management. Lung Cancer. 2003 Dec; 42 Suppl 1:S7-8.
    View in: PubMed
    Score: 0.045
  45. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997 Apr; 113(4):691-8; discussion 698-700.
    View in: PubMed
    Score: 0.028
  46. An historical perspective of multi-modality treatment for resectable non-small cell lung cancer. Lung Cancer. 1995 Jun; 12 Suppl 2:S17-32.
    View in: PubMed
    Score: 0.025
  47. Age is a strong risk factor for atrial fibrillation after pulmonary lobectomy. Am J Surg. 2010 Apr; 199(4):558-61.
    View in: PubMed
    Score: 0.018
  48. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg. 1996 Mar; 61(3):977-82.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.